This program has been supported by an independent educational grant from Gilead Sciences, Inc.
In anticipation of new anti-CD47 therapies in practice, clinical laboratory and blood bank personnel ¾ including pathologists, phlebotomists, nurses, and collections managers ¾ need to prepare for strategies that address the effects of anti-CD47 mAb therapy on RBCs, compatibility testing, and transfusion requirements. Please join a panel of experts in hematology, transfusion medicine, and blood banking for a live, interactive symposium at the AABB 2023 Annual Meeting in Nashville, TN. This fun and engaging event will include “escape room” challenges, as participants compete to apply key concepts presented by the faculty to virtual clinical and laboratory-based simulations. Don’t miss this unique opportunity to stay ahead of the curve in learning about the clinical and blood management implications of anti-CD47 therapy. Perhaps you’ll see your name atop the leaderboard!
All relevant financial relationships have been mitigated.
By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.
AM23-ST-06-O: Deciphering the Clinical Clues: Updates to Protocols and Procedures for Anti-CD47 Agents in Clinical Laboratories (Enduring) Evaluation